Background: With the exception of PD-L1 expression for pembrolizumab, no biomarkers allow to maximize the benefit of immunotherapy in advanced pretreated non-small-cell lung cancer (AP-NSCLC). The genomic abnormalities of genes involved in immune-escape/editing are suggested as baseline mechanisms of resistance. Method: A retrospective series of AP-NSCLC patients (pts) undergone Nivolumab (NIVO) was collected. FFPE-tumor blocks were analyzed to identity somatic mutations (SMs)/ copy number variations (CNVs) with a Ampliseq CGS panel (17 genes: APLNR, B2M, IFNAR1, IFNAR2, IFNGR1, IFNGR2, IRF9, JAK1, JAK2, JAK3, PIAS4, PTPN2, SOCS1, STAT1, STAT2, STAT3 and TYK2). End-points were overall-, progression-free-survival (OS/PFS) and objective response rate (ORR). Result: Data from 24 consecutive AP-NSCLC pts who received NIVO were gathered (median age 69.5 yrs, median number of previous lines 3 [2-5], 2nd line NIVO [70.8%], median follow-up 6.8 months [range 1-23], deaths 14 [58.3%], male/female 79.2/20.8%, squamous/non-squamous 41.7/58.3%, EGFR mutant 5 [20.8%])
P2.04-13 The Immune Checkpoint, HVEM Contribute to Immune Escape in Non Small Cell Lung Cancer of Lacking PDL1 Expression S. Ren, 1 H. Yu, 2 C. Rivard, 2 K. Suda, 3 C. Caldwell Jr., 4 L. Rozeboom, 5 T. Ng, 6 G. Rivalland, 7 P. Mitchell, 8 Background: Herpes Virus Entry Mediator (HVEM) is an important immune checkpoint in cancer recognition. HVEM expressed on tumor cell membranes activates immune cell signaling pathways leading to either inhibition of activity (BTLA) or activation of immune activity (LIGHT). The aim of this study is to investigate the prevalence of HVEM expression and its association with PDL1 expression in NSCLC. Method: A TMA of 527 resected NSCLC samples and 53 NSCLC cell lines were evaluated for HVEM and PD-L1 expression. The IHC assay for HVEM was optimized on the Dako Link48 autostainer using a polyclonal antibody from RandD Systems (AF356). PD-L1 IHC was performed on the Dako Link48 autostainer using the PD-L1 22C3 pharmDx kit. Scoring HVEM employed the Hscore system while for PD-L1 the tumor proportion score (TPS) was used. Result: HVEM expression in the NSCLC resected samples and cell lines revealed a positive H-score more than 1 was18.6%(77/415) and 45.3%(24/53) respectively. HVEM expression was significantly higher in patients with lymph node N2 metastasis (25.5% vs 7.9% vs 17.5%, P¼0.046) when comparing with N1 or no lymph node metastasis, and was marginally significantly higher in patients with stage III/IV disease (24.5% vs 16.4%, P¼0.059). Subgroup analysis showed that HVEM (median 45 vs 36 months, p¼0.706) and PD-L1 expression (median 45 vs 48 months, p¼0.178) status was not predictive of overall survival. HVEM was found to have a significant negative correlation with PD-L1 expression (r¼-0.232, p¼0.002, Figure 1A ) in patients with NSCLC and also have a negative correlation in NSCLC cell lines(r¼-0.055, p¼0.764, Figure 1B) . Conclusion: HVEM was found to be overexpressed in patients of NSCLC with advanced disease or lymph node metastasis and has a negative corelationship with PD-L1 expression, while, it did not have a prognostic role in patients with NSCLC. Background: Immune checkpoint inhibitors (ICI) improve overall survival in non-small cell lung cancer (NSCLC) in the 2 nd -line setting and lead to prolonged disease control in a subgroup of patients (pts). Robust predictive biomarkers for ICI are highly desired. In an exploratory analysis of the CheckMate 026 study, high tumor mutation burden (TMB) assessed by whole-exome sequencing was associated with improved outcome of pts treated with nivolumab. Method: From our institutional database, 41 pts with metastatic NSCLC were included
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